COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) USING A TREAT-AND-EXTEND REGIMEN: RESULTS OF THE 24-MONTH SECONDARY EFFICACY OUTCOMES FROM THE RIVAL STUDY, A RANDOMIZED CLINICAL TRIAL

Alex P. Hunyor; Jennifer Arnold; Ian L. McAllister; Francois L. Pecheur; Ronelle-Mare Heath; Robyn H. Guymer; Marc C. Gillies

COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) USING A TREAT-AND-EXTEND REGIMEN: RESULTS OF THE 24-MONTH SECONDARY EFFICACY OUTCOMES FROM THE RIVAL STUDY, A RANDOMIZED CLINICAL TRIAL

Alex P. Hunyor, Jennifer Arnold, Ian L. McAllister, Francois L. Pecheur, Ronelle-Mare Heath, Robyn H. Guymer, Marc C. Gillies

Centre for Ophthalmology and Visual Science (affiliated with the Lions Eye Institute)

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Article number	S1502
Pages (from-to)	42-42
Number of pages	1
Journal	Clinical and Experimental Ophthalmology
Volume	46
Publication status	Published - Nov 2018

Cite this

Hunyor, A. P., Arnold, J., McAllister, I. L., Pecheur, F. L., Heath, R.-M., Guymer, R. H., & Gillies, M. C. (2018). COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) USING A TREAT-AND-EXTEND REGIMEN: RESULTS OF THE 24-MONTH SECONDARY EFFICACY OUTCOMES FROM THE RIVAL STUDY, A RANDOMIZED CLINICAL TRIAL. Clinical and Experimental Ophthalmology, 46, 42-42. Article S1502.

Hunyor, Alex P. ; Arnold, Jennifer ; McAllister, Ian L. et al. / COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) USING A TREAT-AND-EXTEND REGIMEN : RESULTS OF THE 24-MONTH SECONDARY EFFICACY OUTCOMES FROM THE RIVAL STUDY, A RANDOMIZED CLINICAL TRIAL. In: Clinical and Experimental Ophthalmology. 2018 ; Vol. 46. pp. 42-42.

@article{85a76e3e3c25428c94cdbe8553084135,

title = "COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) USING A TREAT-AND-EXTEND REGIMEN: RESULTS OF THE 24-MONTH SECONDARY EFFICACY OUTCOMES FROM THE RIVAL STUDY, A RANDOMIZED CLINICAL TRIAL",

author = "Hunyor, {Alex P.} and Jennifer Arnold and McAllister, {Ian L.} and Pecheur, {Francois L.} and Ronelle-Mare Heath and Guymer, {Robyn H.} and Gillies, {Marc C.}",

year = "2018",

month = nov,

language = "English",

volume = "46",

pages = "42--42",

journal = "Clinical and Experimental Ophthalmology",

issn = "1442-6404",

publisher = "John Wiley & Sons",

}

Hunyor, AP, Arnold, J, McAllister, IL, Pecheur, FL, Heath, R-M, Guymer, RH & Gillies, MC 2018, 'COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) USING A TREAT-AND-EXTEND REGIMEN: RESULTS OF THE 24-MONTH SECONDARY EFFICACY OUTCOMES FROM THE RIVAL STUDY, A RANDOMIZED CLINICAL TRIAL', Clinical and Experimental Ophthalmology, vol. 46, S1502, pp. 42-42.

COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) USING A TREAT-AND-EXTEND REGIMEN: RESULTS OF THE 24-MONTH SECONDARY EFFICACY OUTCOMES FROM THE RIVAL STUDY, A RANDOMIZED CLINICAL TRIAL. / Hunyor, Alex P.; Arnold, Jennifer; McAllister, Ian L. et al.
In: Clinical and Experimental Ophthalmology, Vol. 46, S1502, 11.2018, p. 42-42.

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

TY - JOUR

T1 - COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) USING A TREAT-AND-EXTEND REGIMEN

T2 - RESULTS OF THE 24-MONTH SECONDARY EFFICACY OUTCOMES FROM THE RIVAL STUDY, A RANDOMIZED CLINICAL TRIAL

AU - Hunyor, Alex P.

AU - Arnold, Jennifer

AU - McAllister, Ian L.

AU - Pecheur, Francois L.

AU - Heath, Ronelle-Mare

AU - Guymer, Robyn H.

AU - Gillies, Marc C.

PY - 2018/11

Y1 - 2018/11

M3 - Abstract/Meeting Abstract

SN - 1442-6404

VL - 46

SP - 42

EP - 42

JO - Clinical and Experimental Ophthalmology

JF - Clinical and Experimental Ophthalmology

M1 - S1502

ER -

Hunyor AP, Arnold J, McAllister IL, Pecheur FL, Heath RM, Guymer RH et al. COMPARISON OF RANIBIZUMAB AND AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) USING A TREAT-AND-EXTEND REGIMEN: RESULTS OF THE 24-MONTH SECONDARY EFFICACY OUTCOMES FROM THE RIVAL STUDY, A RANDOMIZED CLINICAL TRIAL. Clinical and Experimental Ophthalmology. 2018 Nov;46:42-42. S1502.